management-header-3.jpg

Meet the minds behind our innovation.

Marinus Pharmaceuticals’ management team is committed to developing ganaxolone for treatment of drug-resistant seizures and neuropsychiatric disorders in both the hospital and home settings.

headshot ed smith

Ed has more than 20 years of executive finance and operational leadership experience in publicly traded biotechnology companies from early stage through commercial stage.

Edward F. Smith, Vice President, Chief Financial Officer, Secretary and Treasurer

Ed has more than 20 years of executive finance and operational leadership experience in publicly traded biotechnology companies from early stage through commercial stage. As CFO of Marinus, Ed oversees finance, accounting, information technology, operations, human resources, and investor relations. Throughout his career, he has raised hundreds of millions of dollars from IPOs, follow-on equity raises, private placements, convertible securities, and debt issuances. Prior to Marinus, Ed served as CFO of PolyMedix, Inc., and executive director of finance at InKine Pharmaceutical Company, Inc., where he assisted with the acquisition of the company by Salix Pharmaceuticals, Inc. Earlier in his career, Ed held various positions of increasing responsibility in public accounting, most recently in the audit practice at Deloitte & Touche, LLP.

Ed holds a B.S. in business administration from the University of Hartford and was licensed as a Certified Public Accountant in Pennsylvania.

icon patient resources

Explore Patient Resources

Find helpful information and patient networks, as well as clinical trial opportunities.

View Patient Resources

icon join marinus team

Join the Marinus Team

Learn how you can become part of our mission to advance mindful innovation.

Visit Careers Center